HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

导出 OA

翻译打印收藏纠错

第一作者： S,Tharkar-Promod

第一单位： Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT, USA.

作者： S,Tharkar-Promod ^[1] ; D P,Johnson ^[2] ; S E,Bennett ^[2] ; E M,Dennis ^[3] ; B G,Banowsky ^[1] ; S S,Jones ^[2] ; J R,Shearstone ^[1] ; S N,Quayle ^[2] ; C,Min ^[1] ; M,Jarpe ^[2] ; T,Mosbruger ^[4] ; A D,Pomicter ^[5] ; R R,Miles ^[4] ; W Y,Chen ^[4] ; K N,Bhalla ^[4] ; P A,Zweidler-McKay ^[5] ; D C,Shrieve ^[2] ; M W,Deininger ^[2] ; M B,Chandrasekharan ^[6] ; S,Bhaskara ^[7]

作者单位： Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT, USA. ^[1] Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. ^[2] Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA. ^[3] Acetylon Pharmaceuticals Inc., Boston, MA, USA. ^[4] Regenacy Pharmaceuticals Inc., Boston, MA, USA. ^[5] Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. ^[6] Department of Cancer Biology, City of Hope National Medical Center, Duarte, CA, USA. ^[7] Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[8] Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. ^[9] Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[10]